Literature DB >> 27364047

Long-Term Mortality After Coronary Revascularization in Nondiabetic Patients With Multivessel Disease.

Mineok Chang1, Jung-Min Ahn1, Cheol Whan Lee2, Rafael Cavalcante3, Yohei Sotomi4, Yoshinobu Onuma3, Erhan Tenekecioglu3, Minkyu Han5, Duk-Woo Park1, Soo-Jin Kang1, Seung-Whan Lee1, Young-Hak Kim1, Seong-Wook Park1, Patrick W Serruys6, Seung-Jung Park1.   

Abstract

BACKGROUND: In diabetic patients with multivessel coronary artery disease (CAD), the survival difference between coronary artery bypass graft (CABG) surgery and percutaneous coronary intervention (PCI) favors CABG. However, there are few data on the mortality difference between the 2 strategies in nondiabetic patients.
OBJECTIVES: This study performed a patient-level meta-analysis to compare the effect of CABG versus PCI with drug-eluting stents on long-term mortality in 1,275 nondiabetic patients with multivessel CAD.
METHODS: Individual patient data from the SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) and the BEST (Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease) trials were pooled. The primary outcome was death from any cause.
RESULTS: The median follow-up time was 61 months (interquartile range: 50 months to 62 months). The risk of death from any cause was significantly lower in the CABG group than in the PCI group (hazard ratio [HR]: 0.65; 95% confidence interval [CI]: 0.43 to 0.98; p = 0.039). A similar finding was observed for the risk of death from cardiac causes. The superiority of CABG over PCI was consistent across the major clinical subgroups. Likewise, the rate of myocardial infarction was remarkably lower after CABG than after PCI (HR: 0.40; 95% CI: 0.24 to 0.65; p < 0.001). However, the rate of stroke was not different between the 2 groups (HR: 1.13; 95% CI: 0.59 to 2.17; p = 0.714). The need for repeat revascularization was significantly lower in the CABG group than in the PCI group (HR: 0.55; 95% CI: 0.40 to 0.75; p < 0.001).
CONCLUSIONS: CABG, as compared with PCI with drug-eluting stents, significantly reduced the long-term risk of mortality in nondiabetic patients with multivessel CAD.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery bypass graft surgery; drug-eluting stents; multivessel coronary artery disease

Mesh:

Year:  2016        PMID: 27364047     DOI: 10.1016/j.jacc.2016.04.034

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  Impact of left main coronary artery disease on long-term mortality in patients undergoing drug-eluting stent implantation.

Authors:  Se Hun Kang; Cheol Whan Lee; Seunghee Baek; Pil Hyung Lee; Jung-Min Ahn; Duk-Woo Park; Soo-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Seong-Wook Park; Seung-Jung Park
Journal:  Clin Res Cardiol       Date:  2017-08-03       Impact factor: 5.460

2.  Prognostic superiority of coronary artery bypass grafting to percutaneous coronary intervention in non-diabetic patients with anatomically complex multivessel coronary artery disease.

Authors:  Kenji Sakata; Takuya Nakahashi; Masa-Aki Kawashiri
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

3.  Choosing between percutaneous coronary intervention and coronary artery bypass graft surgery for nondiabetic patients with multivessel disease.

Authors:  Aeshita Dwivedi; Sripal Bangalore
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

4.  Coronary revascularization strategies in patients with multivessel disease: is it all about diabetes?

Authors:  Sergio Buccheri; Davide Capodanno
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

5.  Coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in the treatment of multivessel coronary disease: quo vadis? -a review of the evidences on coronary artery disease.

Authors:  Cristiano Spadaccio; Umberto Benedetto
Journal:  Ann Cardiothorac Surg       Date:  2018-07

6.  Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy.

Authors:  Laura S Kerkmeijer; Serdar Farhan; Roxana Mehran; George D Dangas
Journal:  Ann Transl Med       Date:  2017-06

Review 7.  Can We Improve the Outcomes of Multivessel Disease Using Modified SYNTAX and Residual SYNTAX Scores?

Authors:  Alfredo E Rodriguez; Carlos Fernandez-Pereira; Juan Mieres; Javier Mendoza; Florencia Sartori
Journal:  Curr Cardiol Rep       Date:  2017-03       Impact factor: 2.931

Review 8.  Percutaneous Coronary Intervention with Stenting versus Coronary Artery Bypass Grafting in Stable Coronary Artery Disease.

Authors:  Ian C Glenn; Gabriele M Iacona; Abeel A Mangi
Journal:  Int J Angiol       Date:  2021-08-31

9.  Understanding the Outcome of Randomized Trials with Drug-Eluting Stents and Coronary Artery Bypass Graft in Patients with Multivessel Disease: A Review of a 25-Year Journey.

Authors:  Alfredo E Rodriguez; Hernán Pavlovsky; Juan Francisco Del Pozo
Journal:  Clin Med Insights Cardiol       Date:  2016-12-07

10.  A Rabbit Model for Testing Helper-Dependent Adenovirus-Mediated Gene Therapy for Vein Graft Atherosclerosis.

Authors:  Lianxiang Bi; Bradley K Wacker; Emma Bueren; Ervin Ham; Nagadhara Dronadula; David A Dichek
Journal:  Mol Ther Methods Clin Dev       Date:  2017-09-28       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.